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T he use of biochemical markers as monitoring toolsfor disease or organ damage is widespread and uni-
versal. Much work was carried out in the 1960s and
1970s in the characterization of creatine kinase and its
isoenzymes to determine whether myocardial damage
occurred after cardiac surgery. Only through careful
determination of the presence of isoenzymes and the
sites and rates of expression and degradation was useful
information gathered. An ideal biochemical marker
should be organ specific, quantitative, and predictable,
and its kinetics should be understood. Four articles in
this issue address the use of biochemical markers to
estimate potential brain injury in patients undergoing a
variety of cardiac operations. The results presented in
these manuscripts reflect the fact that the development
of a biochemical marker for cerebral injury is limited by
several unique problems. Because the brain is not
homogeneous, the site of an injury as opposed to the
size of an injury determines the degree of functional
impairment. Within the brain, there are a variety of cell
types, all differing in cellular architecture and makeup.
The blood-brain barrier further complicates the picture. 
In the papers contained in this issue, S-100 proteins
and neuron-specific enolase (NSE) have been used to
estimate brain injury after cardiac surgery. Much has
been written regarding these two markers of cerebral
damage. The purpose of this editorial is to try to clarify
the results presented in this issue as they relate to our
current knowledge. 
S-100 proteins are a group of acidic, calcium-binding
proteins found in high concentrations in the nervous
system.1 They are dimers of the α β subunits presenting
in various concentrations in glial and Schwann cells, as
well as striated muscle, heart, and kidney. These pro-
teins are metabolized and excreted by the kidney with a
half-life of 113 minutes in plasma.2 The normal, in vivo
level, of S-100β is undetectable by currently available
assays. NSE is a dimeric, glycolytic enzyme located in
neurons.3 It may also be produced by small cell lung
cancer and tumors of neuroendocrine origin.4 Un-
fortunately, it is also present in platelets and erythro-
cytes, which can lead to errors in interpretation because
a small degree of hemolysis or platelet damage can sub-
stantially increase plasma levels.5
After brain injury, S-100β and NSE are detectable in
the cerebral spinal fluid. After an acute stroke, serum
levels of both S-100 and NSE are elevated.6 Unlike
NSE, S-100β levels appear to be related to the volume of
brain damage and clinical outcome in acute stroke.7
Because of the relationship to the volume of injured
brain, many investigators have attempted to use postop-
erative S-100β levels to estimate the amount of brain
injury in patients undergoing cardiac surgery. In our own
experience, as well as the experience of others including
papers published in this issue, the amount of S-100
begins to rise in the serum during cardiopulmonary
bypass and reaches a peak 24 to 36 hours after the oper-
ation. This is similar to the findings in acute stroke.
Because the isoforms of S-100 are found in high concen-
trations in Schwann cells and glial cells, which are preva-
lent in the white matter of the brain, we postulate that the
release of S-100β during cardiopulmonary bypass
reflects changes in white matter.8 Harris and associates9
have reported that patients studied preoperatively and
postoperatively with cerebral magnetic resonance imag-
ing demonstrate cerebral edema predominately in white
matter. The mechanism of the brain swelling is uncer-
tain but is probably related to a combined effect of
hemodilution and membrane changes in the brain, per-
haps related to the generalized inflammatory reaction
produced by cardiopulmonary bypass. This swelling is
unaffected by cardiopulmonary bypass temperature and
disappears within 7 days after the operation.10
Because isoforms of S-100 are located in multiple
sites in the body, there has been much speculation as to
elevated S-100β levels in patients exposed to cardiopul-
monary bypass who do not have clinical brain injury.
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Johnsson11 has recently postulated that the increased lev-
els of S-100 during and after cardiopulmonary bypass may
be related in part to a previously overlooked extracerebral
source, which is thought to be lipolysis of fat from medi-
astinal tissue that enters the circulation via cardiotomy
suction, or retransfusion of shed blood postoperatively.
Very few patients undergoing cardiopulmonary bypass
have acute stroke. Therefore other measures of brain
function have been used to quantitate cerebral injury in
patients after cardiopulmonary bypass. Neurocognitive or
neuropsychologic testing has been used to quantitate
brain function preoperatively and postoperatively and has
been found to be abnormal for at least 7 to 30 days in as
many as 60% of patients undergoing cardiopulmonary
bypass for a variety of operations.12 Unfortunately, it has
been difficult to establish a consistent correlation between
the results of S-100 elevations and abnormal neuropsy-
chologic performance after surgery.13 The reasons for this
are intuitive. Abnormal neuropsychologic performance is
primarily related to defects in gray matter, whereas white
matter alterations seem to be responsible for elevations of
S-100. Therefore it may be difficult to correlate these two
measures of brain injury postoperatively although the two
may be complementary. 
In this issue, Svensson and associates were able to
find a correlation between early changes in neuropsy-
chologic performance and S-100 elaboration. It is
important to note that their model (patients undergoing
circulatory arrest for aortic arch procedures) was the
most severe model and exposed the brain to potentially
injurious generalized hypoperfusion. Therefore the
changes seen in Svensson’s patients would be general-
ized and not related to gray or white matter exclusively.
Even with the elevations of S-100β and decrements of
cognitive function seen 1 week after the operation, no
patients had acute stroke and had returned to normal
cognitive function in 1 month. It is reasonable to assume
that membrane changes in glial cells are responsible for
both white matter edema and elaboration of S-100β.
The time courses for the disappearance of both cerebral
edema and serum levels of S-100β are similar.
The critical question that would benefit surgeons per-
forming cardiac operations is this: Do small elevations
of S-100 during and after cardiopulmonary bypass indi-
cate permanent brain injury? This question cannot be
accurately answered at this point, but some generaliza-
tions can be made. Because postoperative S-100 levels
are not consistently correlated with transient neurolog-
ic or neuropsychologic abnormalities, it is unlikely that
mild to moderate elevations of S-100 are associated
with clinically detectable permanent brain injury.
Moreover, our clinical data suggest that S-100 levels
are more related to the duration of cardiopulmonary
bypass and not to the number of emboli delivered to the
brain, as measured by Doppler ultrasound, nor to the
postoperative neuropsychologic performance.14 In
addition, since S-100 is cleared by the kidneys, studies
measuring S-100 should correlate the serum levels with
the clearance. This will be very similar to the relation-
ship between serum creatinine levels and the creatinine
clearance in patients after cardiac surgery. 
It appears certain that articles in which biochemical
markers have been used to measure brain injury will
continue to appear. As investigators more clearly iden-
tify the significance of elevated markers of brain injury,
the clinical role for these findings will be further eluci-
dated. At this point, this role is not yet clear. 
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